Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118338) titled 'Dapagliflozin combined with next-generation hormonal agent (NHA) versus single NHA in participants with metastatic castrate-resistant prostate cancer: a multicenter, open-label, randomized controlled trial' on Feb. 4.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
metastatic castration-resistant prostate cancer
Intervention:
Intervention group:Dapagliflozin combined with next-generation hormonal agents plus androgen deprivation therapy
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrol...